Key Takeaways Pediatrix Medical's Q3 EPS rose 52.3% year over year, beating consensus by 45.7%.Same-unit revenues climbed 8% on stronger reimbursement factors and patient acuity.Operating expenses fell 11%, helping EBITDA jump 45% and net income reach $71.7 million.Pediatrix Medical Group, Inc. (MD) reported third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which surpassed the Zacks Consensus Estimate by 45.7%. The bottom line surged 52.3% year over year.Net revenues tumbled 3.6% year over y ...

Figure 1 Labrador Trough Alliance Malaco Mountain Project Figure 2 2025 Rock Samples Location on the Malaco Mountain Project Figure 3 Rock Samples Collected on Malaco Mountain Project (Sept. 2025) MONTREAL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with SOQUEM Inc. (“SOQUEM”), is pleased to announce new assay results for the Malaco Mountain copper, gold, and rare earth elements (REE) zone discovered in June 2025 in the Labrador Trough ( ...

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q3 2025 was $87 million, exceeding expectations, with a full-year adjusted EBITDA outlook of $270-$290 million [4][6] - Consolidated revenue decreased by just under $54 million due to portfolio restructuring, partially offset by strong same-unit growth of 8% and same-unit pricing up about 7.5% [6][8] - Operating cash flow generated in Q3 was $138 million, compared to $96 million in the prior year, driven by higher earnings and increased cash flow from accounts receivable [8][9] Business Line Data and Key Metrics Changes - Same-unit pricing increase was driven by solid revenue cycle management (RCM) cash collections, increased patient acuity in neonatology, and an increase in contract administrative fees [6][28] - Salary growth for the third quarter was modestly below the previous five-quarter average of 3-3.5% [7] - A net gain on investments in divested businesses was $21 million, contributing to other non-operating income [7] Market Data and Key Metrics Changes - The company maintained a strong market position with over 1,300 physicians and 1,170 advanced practice providers across 322 locations in 33 states [11] - The company has a comprehensive clinical data warehouse with 37 million patient days and 2 million NICU admissions, supporting its research productivity [11] Company Strategy and Development Direction - The company is focused on enhancing technological support and has developed a proprietary system called BabySTEPS to assist clinicians in caring for high-risk NICU patients [12][13] - The company aims to strengthen its operations in pediatric surgery, neurology, and cardiac intensive care, while continuing to build partnerships with hospital systems [16][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledges significant healthcare headwinds but sees many opportunities to strengthen operations and results [17] - The company is optimistic about the potential benefits of exchange credits for expecting mothers, although the exact impact remains uncertain [37] Other Important Information - The company repurchased 1.2 million shares in the quarter, totaling 1.7 million shares to date [4] - The company ended the quarter with cash of $340 million and net debt of just over $260 million, reflecting a net leverage of just under one times [9] Q&A Session Summary Question: Thoughts on capital deployment and share repurchase - Management has been aggressively buying back shares and is exploring various opportunities for growth, both internally and externally [20] Question: Impact of portfolio restructuring on market dynamics - Management believes the restructuring has strengthened the company’s focus and improved the environment for recruiting new practices [21][22] Question: Breakdown of strong pricing in the quarter - Strong pricing was driven by RCM collections, increased acuity, and contract administrative fees, with expectations for stability in payer mix [27][28] Question: Guidance on seasonality and volume factors - Management indicated that there are no significant changes in volumes expected, but variability may arise as the year ends [30][31] Question: Long-term outlook and potential opportunities - Management is optimistic about future partnerships with hospital systems and believes financial strength will provide additional opportunities [38][40]

Financial Performance - Net revenue for the three months ended September 30, 2025, was $492.9 million, a decrease of $18.3 million, or 3.6%, compared to $511.2 million in the same period in 2024[77]. - Same-unit net revenue increased by $35.6 million, or 8.0%, driven by a $33.9 million increase from net reimbursement-related factors and a $1.7 million increase from patient service volumes[77]. - Income from operations increased by $34.3 million, or 101.2%, to $68.1 million for the three months ended September 30, 2025, with an operating margin of 13.8% compared to 6.6% in 2024[85]. - Adjusted EBITDA for the three months ended September 30, 2025, was $87.3 million, compared to $60.2 million for the same period in 2024[88]. - Net income for the three months ended September 30, 2025, was $71.7 million, compared to $19.4 million in 2024[88]. - For the nine months ended September 30, 2025, net revenue was $1.42 billion, a decrease of $90.5 million, or 6.0%, compared to $1.51 billion in 2024[90]. - Adjusted EPS for the three months ended September 30, 2025, was $0.67, compared to $0.44 for the same period in 2024[89]. - Total non-operating income was $19.7 million for the three months ended September 30, 2025, compared to total non-operating expenses of $8.6 million in 2024[86]. - Income from operations increased by $268.0 million, or 248.2%, to $160.0 million for the nine months ended September 30, 2025, compared to a loss of $108.0 million in 2024[98]. - Net income was $131.7 million for the nine months ended September 30, 2025, compared to a net loss of $129.5 million for the same period in 2024[101]. - Adjusted EBITDA rose to $209.7 million for the nine months ended September 30, 2025, from $155.3 million in 2024[101]. - Cash provided by operating activities was $160.1 million for the nine months ended September 30, 2025, compared to $82.4 million for the same period in 2024[106]. - Days sales outstanding (DSO) improved to 43.1 days at September 30, 2025, down from 51.6 days at September 30, 2024[108]. - Total non-operating income was $10.8 million for the nine months ended September 30, 2025, compared to net non-operating expenses of $26.7 million in 2024[99]. Operational Changes - As of December 31, 2024, the exits of pediatric office-based practices were completed, with a focus returning to hospital-based and maternal-fetal medicine services[66]. - The company exited its primary and urgent care service line during 2024 due to the high costs and time required to scale[66]. - The company operates a national network of affiliated physicians providing services in 37 states, focusing on neonatal and maternal-fetal care[64]. - The company is transitioning to a hybrid revenue cycle management model, which is part of its transformation initiatives[124]. - The company is focusing on growth strategies for its hospital-based and maternal-fetal businesses[124]. - The company is assessing the timing and contribution of future acquisitions or organic growth initiatives[124]. Regulatory and Market Risks - The No Surprises Act, effective January 1, 2022, limits out-of-network providers from sending surprise medical bills, which could materially affect the company's financial condition and results of operations[67][69]. - The Patient Protection and Affordable Care Act has altered healthcare delivery and reimbursement, with potential changes that could adversely impact the company's business[70]. - The One Big Beautiful Bill Act, signed into law on July 4, 2025, reforms the Medicaid program, which may affect reimbursements for services provided by the company[72]. - The effects of economic conditions and healthcare reforms, including the Medicare Access and CHIP Reauthorization Act, are being monitored for their impact on the business[124]. - Relationships with government-sponsored healthcare programs and managed care organizations are critical to the company's operations[124]. - The company is facing risks related to state budgetary constraints and uncertainty over the future of Medicaid[124]. - The company is subject to market risk primarily from exposure to changes in interest rates due to its financing and investing activities[125]. - A 1% change in interest rates would result in an impact to income before taxes of approximately $2.0 million per year[125]. - The company intends to manage interest rate risk through a combination of fixed rate and variable rate debt[125]. Cost Management - The company has experienced rising costs of managed care premiums and patient responsibility amounts, leading to increased bad debt[65]. - General and administrative expenses were $60.8 million for the three months ended September 30, 2025, an increase of $2.7 million from $58.1 million in 2024, with expenses as a percentage of net revenue rising to 12.3% from 11.4%[81]. - Practice salaries and benefits decreased by $32.6 million, or 8.9%, to $332.3 million for the three months ended September 30, 2025[79]. - Transformational and restructuring related expenses were $16.4 million for the nine months ended September 30, 2025, down from $40.6 million for the same period in 2024[96]. Cash and Debt Management - As of September 30, 2025, cash and cash equivalents were $340.1 million, up from $229.9 million at December 31, 2024[104]. - The company had an outstanding principal balance of $201.6 million on the Amended Credit Agreement as of September 30, 2025[116]. - The company anticipates that funds generated from operations will be sufficient to finance working capital requirements and fund anticipated acquisitions for at least the next 12 months[121]. - The company had an outstanding principal balance of $201.6 million on its Amended Credit Agreement under the Term A Loan as of September 30, 2025[125].

FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Third Quarter Results Raises Full Year 2025 Adjusted EBITDA Outlook Range FORT LAUDERDALE, Fla., November 3, 2025 - Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.84 per share for the three months ended September 30, 2025. On a non-GAAP basis, Ped ...

Key Takeaways Pediatrix Medical will release third-quarter 2025 results on Nov. 3, before the opening bell.Q3 EPS estimate of 46 cents implies 4.6% growth, but revenue estimate of $484.1M signals a 5.3% drop.Lower operating expenses, including salaries and G&A, may help boost Pediatrix Medical's bottom line.Pediatrix Medical Group, Inc. (MD) is set to report its third-quarter 2025 results on Nov. 3, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and rev ...

Core Insights - Midland Exploration Inc. announced positive gold results from its Caniapisc Au project, indicating a successful follow-up exploration program that identified new gold-bearing boulders and significant assay values [1][3][4] Exploration Program Details - The autumn exploration program included geological mapping, prospecting, soil sampling, and a 2,001-kilometre magnetic and electromagnetic geophysical survey [3][4][9] - A total of 111 grab rock samples and 112 soil samples were collected during the follow-up campaign, with results for soil samples still pending [3][5] Key Findings - The exploration program identified several new gold-bearing boulders, with a maximum assay value of 24.5 g/t Au from a selected grab sample [4][8] - Out of the rock samples, 16 returned gold values exceeding 0.5 g/t, including eight samples greater than 2.0 g/t Au [4][5] - A specific boulder returned a value of 19.2 g/t Au, while another returned 11.9 g/t Au, indicating a promising mineralization potential in the area [8] Geological Context - The Caniapisc Au project is located within the Ashuanipi Subprovince, characterized by a volcanosedimentary belt with historical exploration highlighting the potential for various mineralizations [10] - Previous till sampling surveys in the area identified gold anomalies, suggesting further exploration opportunities [10] Quality Control Measures - Rock and soil samples were analyzed at Actlabs laboratories, employing industry-standard quality assurance and control practices [12]

Core Insights - Pediatrix Medical Group has scheduled its 2025 Third Quarter Conference Call/Webcast for November 3, 2025 [1] Company Information - The conference call/webcast is part of the company's ongoing communication strategy with stakeholders [1]

Core Insights - Midland Exploration Inc. has initiated an induced polarization (IP) survey on its Jouvex gold property, located approximately 10 kilometers northwest of the Douay deposit [2] - The Jouvex property is now the main area of interest for upcoming exploration work, particularly in the southern part where new geological features have been identified [4] - A diamond drilling campaign is planned for winter 2026, targeting potential gold-bearing syenite similar to the Douay deposit [5] Exploration Activities - Fieldwork on the Jouvex property resumed in 2024-2025, including two drone-supported magnetic surveys in the southern part of the property [3] - The upcoming IP survey will cover a total of 30 line kilometers and is expected to refine drilling targets based on previous work and recent surveys [3] - Historical drilling data has led to a reassessment of the geology, indicating potential for VMS mineralization in the southern area [4] Future Plans - Midland plans to conduct a diamond drilling campaign totaling at least 1,500 meters in the winter of 2026, focusing on the IP grid established in fall 2025 [5] - Permit applications for the drilling campaign have been submitted and are currently being processed [5] Company Overview - Midland targets the mineral potential of Quebec, aiming to discover new world-class deposits of gold and critical metals [7] - The company collaborates with reputable partners in the mining industry to enhance its exploration efforts and shareholder value [7]

Core Viewpoint - Pediatrix Medical Group (MD) has shown strong stock performance, with a 33.4% increase since the beginning of the year, outperforming the Zacks Medical sector and Zacks Medical Services industry [1][2] Financial Performance - The company has consistently beaten earnings estimates, reporting an EPS of $0.53 against a consensus estimate of $0.42 in its last earnings report [2] - For the current fiscal year, Pediatrix is expected to post earnings of $1.78 per share on revenues of $1.89 billion, reflecting a 17.88% increase in EPS but a 6.3% decrease in revenues [3] - The next fiscal year projections indicate earnings of $1.80 per share on revenues of $1.94 billion, showing a year-over-year change of 1.12% in EPS and 2.63% in revenues [3] Valuation Metrics - Pediatrix Medical Group has a Value Score of A, a Growth Score of A, and a Momentum Score of F, resulting in a combined VGM Score of A [6] - The stock trades at 9.8X current fiscal year EPS estimates, significantly lower than the peer industry average of 17.4X, indicating strong value potential [7] - On a trailing cash flow basis, the stock trades at 9.9X compared to the peer group's average of 10.2X, positioning it favorably for value investors [7] Zacks Rank - The company holds a Zacks Rank of 1 (Strong Buy), driven by rising earnings estimates, making it an attractive option for investors [8][9] Industry Comparison - Compared to industry peers, Charles River Laboratories International, Inc. (CRL) also shows strong performance with a Zacks Rank of 2 (Buy) and solid earnings expectations [10][11] - CRL is expected to post earnings of $10.11 per share on revenues of $3.97 billion for the current fiscal year, with shares gaining 8.1% over the past month [11][12]